Skip to content
2000
image of Impact of Individual and Cassette Administration on Pharmacokinetics of Prednisolone, Diclofenac, and Methotrexate in a Rodent Model of Rheumatoid Arthritis

Abstract

Introduction

To find out how arthritic diseases affect the pharmacokinetics of prednisolone, diclofenac, and methotrexate when given individually and as a cassette in male Sprague-Dawley rats, the study's main goal was to look into drug-drug interactions (DDI). For the treatment of moderate to severe arthritis, doctors commonly prescribe all three drugs alone or in combination.

Methodology

Pharmacokinetics (PK) was evaluated using individual and cassette dosing in male in a fasting state. Respective experimental groups were administered orally with prednisolone (5.0 mg/kg), diclofenac (10.0 mg/kg), and methotrexate (0.5 mg/kg) during either discrete or cassette dosing, at a dose volume of 5 mL/kg. Blood samples were collected through the jugular vein and analyzed by liquid chromatography-tandem mass spectrometry. Pharmacokinetics parameters were calculated using Phoenix software version 8.1.

Results

Prednisolone significantly decreased the AUC0-last in both the arthritic group and the cassette group when compared to the standalone normal animal group. Neither cassette dosing in the normal group nor discrete dosing in the arthritic group affected the pharmacokinetics (PK) of diclofenac. However, the AUC for diclofenac significantly decreased during cassette dosing in the arthritic group. Individual administration of methotrexate in the arthritic group resulted in a significant decrease in AUC0-last, while the healthy group experienced a substantial increase when administered as a cassette.

Discussion

Poly-pharmacy is quite commonly practiced in arthritic patients. Co-administration of multiple drugs together may alter the systemic exposure due to disease condition and drug-drug interaction which ultimately may lead to off target toxicity or sub-therapeutic exposure. The suboptimal therapeutic response may lead to prolonged medication therapy for desired benefit. However, This study has a potential limitation that, diseased induced model may not accurately reflect the human auto-immune disease pathophysiology and further the pharmacokinetics and drug-drug interaction may further vary according to the stage in rheumatoid arthritis patients.

Conclusion

Along with the pharmacological DDI, this study looked at how disease affected the PK of prednisolone, diclofenac, and methotrexate when these drugs were given in both discrete and cassette doses. Significant differences in AUC and C of prednisolone and methotrexate pharmacokinetics when dosed as a cassette or individually in arthritic groups were noticed. The serum concentration of methotrexate increased when it was combined with diclofenac. Further, the metabolism of methotrexate increased when combined with prednisolone.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708344359250414035502
2025-04-28
2025-10-22

  • From This Site

    /content/journals/raiad/10.2174/0127722708344359250414035502
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Radu A.F. Bungau S.G. Management of rheumatoid arthritis: An overview. Cells 2021 10 11 2857 10.3390/cells10112857 34831081
    [Google Scholar]
  2. Rindfleisch J.A. Muller D. Diagnosis and management of rheumatoid arthritis. Am. Fam. Physician 2005 72 6 1037 1047 16190501
    [Google Scholar]
  3. Wang Z. Chen D. Wang Z. Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport. Pharm. Biol. 2018 56 1 269 274 10.1080/13880209.2018.1459740 29651912
    [Google Scholar]
  4. Van Den Abeele J. Brouwers J. Mattheus R. Tack J. Augustijns P. Gastrointestinal behavior of weakly acidic BCS class II drugs in man—case study of diclofenac potassium. J. Pharm. Sci. 2016 105 2 687 696 10.1002/jps.24647 26375734
    [Google Scholar]
  5. Chohan M.S. Elgorashe R.E.E. Balgoname A.A. Eco-friendly derivative UV spectrophotometric methods for simultaneous determination of diclofenac sodium and moxifloxacin in laboratory mixed ophthalmic preparation. Ind J Pharma Educa Res 2019 54 1 166 174 10.5530/ijper.54.1.20
    [Google Scholar]
  6. Tang W. The metabolism of diclofenac--enzymology and toxicology perspectives. Curr. Drug Metab. 2003 4 4 319 329 10.2174/1389200033489398 12871048
    [Google Scholar]
  7. Usui T. Saitoh Y. Komada F. Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol. Pharm. Bull. 2003 26 4 510 517 10.1248/bpb.26.510 12673034
    [Google Scholar]
  8. Bashar T. Apu M.N.H. Mostaid M.S. Islam M.S. Hasnat A. Pharmacokinetics and bioavailability study of a prednisolone tablet as a single oral dose in bangladeshi healthy volunteers. Dose Response 2018 16 3 1559325818783932 10.1177/1559325818783932 30083083
    [Google Scholar]
  9. Yasir M. Goyal A. Sonthalia S. Corticosteroid Adverse Effects. StatPearls. Treasure Island StatPearls Publishing 2022 30285357
    [Google Scholar]
  10. Komura H. Iwaki M. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: Species differences. Drug Metab. Rev. 2011 43 4 476 498 10.3109/03602532.2011.597401 21859377
    [Google Scholar]
  11. Inoue K. Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab. Pharmacokinet. 2014 29 1 12 19 10.2133/dmpk.DMPK‑13‑RV‑119 24284432
    [Google Scholar]
  12. Cheung R.L.H. Lee C. Jones E.J. Riddick D.S. Lack of effect of methotrexate on the expression of constitutive hepatic cytochromes P450 in the male rat. Xenobiotica 1996 26 5 503 514 10.3109/00498259609046728 8736062
    [Google Scholar]
  13. Yokooji T. Yumoto R. Nagai J. Takano M. Yokooji T. Murakami T. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats. J. Pharm. Pharmacol. 2007 59 9 1263 1270 10.1211/jpp.59.9.0011 17883898
    [Google Scholar]
  14. Katherine B. Ashwini G. Tiwari A. Chauhan H. Kumari D. In-vivo studies for drug development via oral delivery: Challenges, animal models and techniques. Pharm. Anal. Acta 2017 8 9 1000560 10.4172/2153‑2435.1000560
    [Google Scholar]
  15. Dunnington K. Benrimoh N. Brandquist C. Cardillo-Marricco N. Spirito M.D. Grenier J. Chapter 4 - Application of Pharmacokinetics in Early Drug Development. In: Pharmacokinetics and Adverse Effects of Drugs. London, UK: InTechOpen 2018 74189 10.5772/intechopen.74189
    [Google Scholar]
  16. Yuan J. Ma H. Cen N. Zhou A. Tao H. A pharmacokinetic study of diclofenac sodium in rats. Biomed. Rep. 2017 7 2 179 182 10.3892/br.2017.942 28781777
    [Google Scholar]
  17. Smith N.F. Raynaud F.I. Workman P. The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery. Mol. Cancer Ther. 2007 6 2 428 440 10.1158/1535‑7163.MCT‑06‑0324 17308044
    [Google Scholar]
  18. Alqahtani S. Bukhari I. Albassam A. Alenazi M. An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: The role of PBPK modeling. Expert Opin. Drug Metab. Toxicol. 2018 14 6 625 634 10.1080/17425255.2018.1482277 29806951
    [Google Scholar]
  19. B Shekhawat P. B Pokharkar V. Understanding peroral absorption: Regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta Pharm. Sin. B 2017 7 3 260 280 10.1016/j.apsb.2016.09.005 28540164
    [Google Scholar]
  20. Tambosi G. Coelho P.F. Luciano S. Challenges to improve the biopharmaceutical properties of poorly water-soluble drugs and the application of the solid dispersion technology. Materia (Rio J.) 2018 23 4 23 10.1590/s1517‑707620180004.0558
    [Google Scholar]
  21. Kim W. Park S. Choi C. Evaluation of anti‐inflammatory potential of the new ganghwaljetongyeum on adjuvant‐induced inflammatory arthritis in rats. Evid. Based Complement. Alternat. Med. 2016 2016 1 1230294 10.1155/2016/1230294 27382402
    [Google Scholar]
  22. Mahdi H.J. Khan N.A.K. Asmawi M.Z.B. Mahmud R. Murugaiyah V. In vivo anti-arthritic and anti-nociceptive effects of ethanol extract of Moringa oleifera leaves on complete Freund’s adjuvant (CFA)-induced arthritis in rats. Integr. Med. Res. 2018 7 1 85 94 10.1016/j.imr.2017.11.002 29629295
    [Google Scholar]
  23. Kumar S. Yadav Ravulapalli S. Kumar Tiwari S. Gupta S. Nair A.B. Jacob S. Effect of sex and food on the pharmacokinetics of different classes of BCS drugs in rats after cassette administration. Int. J. Pharm. 2021 610 121221 10.1016/j.ijpharm.2021.121221 34695535
    [Google Scholar]
  24. Palleria C. Di Paolo A. Giofrè C. Pharmacokinetic drug-drug interaction and their implication in clinical management. J. Res. Med. Sci. 2013 18 7 601 610 24516494
    [Google Scholar]
  25. Lynch T. Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 2007 76 3 391 396 17708140
    [Google Scholar]
  26. Zhang J. Li P. Guo H. Liu L. Liu X. Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund’s complete adjuvant-induced arthritic rats. Acta Pharmacol. Sin. 2012 33 11 1372 1378 10.1038/aps.2012.67 22842736
    [Google Scholar]
  27. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J. Clin. Pharm. Ther. 1999 24 5 339 346 10.1046/j.1365‑2710.1999.00246.x 10583696
    [Google Scholar]
  28. Zhong Z. Sun B. Shu N. Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity. Acta Pharmacol. Sin. 2016 37 7 1002 1012 10.1038/aps.2016.54 27180979
    [Google Scholar]
  29. Brune K. Nürnberg B. Szelenyi I. Vergin H. The enterohepatic circulation of some anti-inflammatory drugs may cause intestinal ulcerations. Side-Effects of Anti-Inflammatory Drugs: Part Two Studies in Major Organ Systems. Rainsford K.D. Velo G.P. Dordrecht Springer Netherlands 1987 29 39 10.1007/978‑94‑010‑9775‑8_2
    [Google Scholar]
  30. Griffin D. Said H.M. The enterohepatic circulation of methotrexate in vivo: Inhibition by bile salt. Cancer Chemother. Pharmacol. 1987 19 1 40 41 10.1007/BF00296253 3815724
    [Google Scholar]
  31. Lafforgue P. Monjanel-Mouterde S. Durand A. Catalin J. Acquaviva P.C. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J. Rheumatol. 1993 20 2 263 267 8474062
    [Google Scholar]
  32. Toda A. Ishii N. Kihara T. Nagamatsu A. Shimeno H. Effect of adjuvant-induced arthritis on hepatic drug metabolism in rats. Xenobiotica 1994 24 7 603 611 10.3109/00498259409043263 7975725
    [Google Scholar]
  33. Lenoir C. Rollason V. Desmeules J.A. Samer C.F. Influence of inflammation on cytochromes P450 activity in adults: A systematic review of the literature. Front. Pharmacol. 2021 12 733935 10.3389/fphar.2021.733935 34867341
    [Google Scholar]
/content/journals/raiad/10.2174/0127722708344359250414035502
Loading
Impact of Individual and Cassette Administration on Pharmacokinetics of Prednisolone, Diclofenac, and Methotrexate in a Rodent Model of Rheumatoid Arthritis
Bentham Science Publishers ; https://doi.org/10.2174/0127722708344359250414035502
/content/journals/raiad/10.2174/0127722708344359250414035502
/content/journals/raiad/10.2174/0127722708344359250414035502
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: PK-PD ; diclofenac ; prednisolone ; Arthritis ; oral drug delivery ; methotrexate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test